Skip to main content
. 2013 Nov 25;8(11):e80687. doi: 10.1371/journal.pone.0080687

Table 2. Pooled ORs and 95% CIs for XRCC1 Arg399Gln, Arg194Trp and Arg280His meta-analysis.

Polymorphism Study group n Codominant Dominant Recessive
Arg399Gln AA vs. GG GA vs. GG AA + GA vs. GG AA vs. GA + GG
(G>A) OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Total 19 1.25 (0.98–1.59) 0.08 1.10 (0.93–1.31) 0.27 1.13 (0.96–1.34) 0.15 1.19 (0.98–1.45) 0.08
Racial decent
Asian 5 1.31 (1.00–1.71) 0.05 1.12 (0.77–1.64) 0.55 1.18 (0.83–1.69) 0.35 1.42 (1.12–1.81) <0.01
Caucasian 11 1.10 (0.68–1.78) 0.69 1.12 (0.86–1.47) 0.40 1.12 (0.85–1.48) 0.44 0.97 (0.68–1.38) 0.87
Unknown 4 1.44 (1.07–1.93) 0.02 1.04 (0.80–1.35) 0.77 1.12 (0.90–1.39) 0.32 1.39 (1.06–1.84) 0.02
Control source
Population 17 1.21 (0.93–1.57) 0.16 1.10 (0.92–1.31) 0.32 1.12 (0.94–1.33) 0.21 1.16 (0.94–1.43) 0.18
Hospital 2 1.62 (0.84–3.11) 0.15 1.19 (0.50–2.82) 0.69 1.27 (0.54–2.98) 0.58 1.54 (0.91–2.58) 0.11
Tumor type
AML 7 0.94 (0.56–1.56) 0.80 0.92 (0.73–1.15) 0.46 0.92 (0.73–1.16) 0.46 0.94 (0.60–1.49) 0.80
Etiology
De novo 4 1.12 (0.48–2.59) 0.79 0.96 (0.59–1.56) 0.87 1.00 (0.65–1.54) 0.99 1.07 (0.50–2.29) 0.86
Secondary 2 0.30 (0.11–0.82) 0.02 0.60 (0.35–1.03) 0.06 0.53 (0.31–0.89) 0.02 0.40 (0.15–1.06) 0.07
Racial decent
Asian 2 1.14 (0.79–1.65) 0.47 0.91 (0.76–1.09) 0.31 0.94 (0.79–1.11) 0.47 1.19 (0.83–1.70) 0.34
Caucasian 5 0.83 (0.32–2.16) 0.71 0.97 (0.60–1.57) 0.90 0.94 (0.59–1.51) 0.80 0.79 (0.35–1.76) 0.56
Control source
Population 7 0.94 (0.56–1.56) 0.80 0.92 (0.73–1.15) 0.46 0.92 (0.73–1.16) 0.46 0.94 (0.60–1.49) 0.80
ALL 8 1.50 (1.11–2.02) 0.01 1.32 (0.99–1.75) 0.06 1.35 (1.02–1.78) 0.03 1.31 (0.99–1.74) 0.06
Racial decent
Asian 2 2.33 (1.25–4.34) 0.01 2.06 (1.44–2.95) < 0.01 2.11 (1.50–2.97) < 0.01 1.69 (0.93–3.07) 0.09
Caucasian 5 1.27 (0.86–1.86) 0.23 1.10 (0.86–1.41) 0.45 1.13 (0.89–1.43) 0.31 1.16 (0.81–1.66) 0.41
Unknown 2 1.55 (0.70–3.43) 0.28 0.76 (0.25–2.28) 0.62 0.88 (0.36–2.16) 0.78 1.61 (0.74–3.47) 0.23
Control source
Population 6 1.47 (1.02–2.11) 0.04 1.45 (1.15–1.83) <0.01 1.45 (1.13–1.85) <0.01 1.23 (0.88–1.72) 0.23
Hospital 2 1.62 (0.84–3.11) 0.15 1.19 (0.50–2.82) 0.69 1.27 (0.54–2.98) 0.58 1.54 (0.91–2.58) 0.11
CML 2 1.05 (0.72–1.55) 0.78 0.81 (0.48–1.36) 0.43 0.86 (0.61–1.21) 0.38 1.26 (0.70–2.26) 0.45
Racial decent
Asian 1 1.14 (0.71–1.85) 0.58 0.63 (0.43–0.92) 0.02 0.72 (0.50–1.05) 0.09 1.62 (1.11–2.38) 0.01
Caucasian 1 0.91 (0.48–1.73) 0.78 1.06 (0.70–1.61) 0.77 1.03 (0.69–1.53) 0.88 0.89 (0.49–1.61) 0.69
Control source
Population 2 1.05 (0.72–1.55) 0.78 0.81 (0.48–1.36) 0.43 0.86 (0.61–1.21) 0.38 1.26 (0.70–2.26) 0.45
CLL 3 1.73 (0.64–4.67) 0.28 1.58 (0.79–3.14) 0.20 1.61 (0.79–3.27) 0.19 1.21 (0.69–2.10) 0.51
Racial decent
Caucasian 2 2.41 (0.22–26.39) 0.47 2.30 (0.52–10.22) 0.27 2.32 (0.43–12.54) 0.33 1.25 (0.36–4.35) 0.72
Unknown 1 1.31 (0.86–1.99) 0.21 1.06 (0.79–1.41) 0.70 1.11 (0.85–1.46) 0.45 1.27 (0.86–1.88) 0.23
Control source
Population 3 1.73 (0.64–4.67) 0.28 1.58 (0.79–3.14) 0.20 1.61 (0.79–3.27) 0.19 1.21 (0.69–2.10) 0.51
Arg194Trp TT vs. CC CT vs. CC TT + CT vs. CC TT vs. CT + CC
(C>T) OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Total 12 1.21 (0.65–2.27) 0.55 1.20 (1.00–1.43) 0.05 1.20 (0.96–1.48) 0.10 1.11 (0.63–1.94) 0.72
Racial decent
Asian 3 0.92 (0.33–2.53) 0.87 1.16 (0.75–1.78) 0.50 1.13 (0.69–1.85) 0.62 0.87 (0.36–2.08) 0.75
Caucasian 6 1.06 (0.20–5.68) 0.94 1.22 (0.81–1.83) 0.34 1.27 (0.77–2.08) 0.35 0.97 (0.22–4.31) 0.97
Unknown 4 1.61 (0.69–3.74) 0.27 1.28 (0.98–1.66) 0.07 1.29 (1.00–1.67) 0.05 1.54 (0.66–3.57) 0.31
Control source
Population 10 1.18 (0.56–2.47) 0.66 1.19 (0.97–1.47) 0.09 1.19 (0.93–1.52) 0.17 1.08 (0.56–2.08) 0.82
Hospital 2 1.32 (0.28–6.33) 0.73 1.24 (0.70–2.18) 0.46 1.27 (0.66–2.45) 0.48 1.27 (0.31–5.19) 0.74
Tumor type
AML 3 1.48 (0.24–9.08) 0.67 1.53 (0.92–2.55) 0.10 1.74 (0.79–3.86) 0.17 1.21 (0.27–5.42) 0.80
Etiology
De novo 2 1.49 (0.03–87.31) 0.85 2.21 (0.69–7.09) 0.18 2.43 (0.43–13.83) 0.32 1.16 (0.04–37.87) 0.94
Secondary 1 1.26 (0.06–27.73) 0.89 1.86 (0.34–10.01) 0.47 1.44 (0.28–7.51) 0.66 1.18 (0.05–25.84) 0.92
Racial decent
Asian 1 1.08 (0.73–1.59) 0.72 1.30 (1.04–1.63) 0.02 1.26 (1.01–1.57) 0.04 0.94 (0.65–1.36) 0.73
Caucasian 2 1.40 (0.02–92.08) 0.87 2.24 (0.73–6.86) 0.16 2.47 (0.45–13.49) 0.30 1.08 (0.03–39.94) 0.97
Control source
Population 3 1.48 (0.24–9.08) 0.67 1.35 (1.09–1.68) 0.10 1.74 (0.79–3.86) 0.17 1.21 (0.27–5.42) 0.80
ALL 6 0.88 (0.28–2.77) 0.82 1.11 (0.85–1.45) 0.46 1.12 (0.80–1.55) 0.51 0.87 (0.30–2.52) 0.79
Racial decent
Asian 2 0.75 (0.07–7.97) 0.81 1.09 (0.48–2.51) 0.84 1.08 (0.40–2.89) 0.88 0.75 (0.09–6.12) 0.79
Caucasian 3 0.60 (0.07–5.11) 0.64 1.14 (0.79–1.64) 0.48 1.10 (0.71–1.68) 0.68 0.58 (0.07–4.68) 0.61
Unknown 2 2.08 (0.57–7.63) 0.27 1.27 (0.78–2.08) 0.34 1.32 (0.82–2.13) 0.25 1.97 (0.54–7.18) 0.30
Control source
Population 4 0.71 (0.13–3.97) 0.70 1.06 (0.75–1.50) 0.75 1.05 (0.69–1.61) 0.82 0.72 (0.14–3.64) 0.69
Hospital 2 1.32 (0.28–6.33) 0.73 1.24 (0.70–2.18) 0.46 1.27 (0.66–2.45) 0.48 1.27 (0.31–5.19) 0.74
CLL 2 1.14 (0.35–3.63) 0.83 1.03 (0.42–2.53) 0.94 1.10 (0.53–2.29) 0.80 1.10 (0.34–3.52) 0.87
Racial decent
Caucasian 1 1.93 (0.08–48.52) 0.69 0.57 (0.20–1.59) 0.28 0.64 (0.23–1.75) 0.38 2.09 (0.08–52.34) 0.65
Unknown 1 1.05 (0.30–3.65) 0.94 1.47 (0.98–2.21) 0.07 1.43 (0.96–2.11) 0.08 1.00 (0.29–3.48) 1.00
Control source
Population 2 1.14 (0.35–3.63) 0.83 1.03 (0.42–2.53) 0.94 1.10 (0.53–2.29) 0.80 1.10 (0.34–3.52) 0.87
Arg280His AA vs. GG GA vs. GG AA + GA vs GG AA vs GA + GG
(G>A) OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Total 6 1.32 (0.56–3.11) 0.52 1.02 (0.82–1.27) 0.87 1.01 (0.78–1.30) 0.97 1.28 (0.55–3.01) 0.57
Racial decent
Asian 4 1.50 (0.57–3.91) 0.41 1.05 (0.73–1.51) 0.79 1.02 (0.68–1.54) 0.91 1.44 (0.55–3.75) 0.46
Unknown 2 0.76 (0.08–7.39) 0.81 0.92 (0.65–1.28) 0.61 0.90 (0.65–1.26) 0.55 0.77 (0.08–7.31) 0.82
Control source
Population 5 1.23 (0.47–3.26) 0.67 0.97 (0.78–1.22) 0.81 0.94 (0.72–1.24) 0.68 1.22 (0.46–3.22) 0.69
Hospital 1 1.68 (0.27–10.31) 0.58 1.42 (0.80–2.50) 0.23 1.43 (0.82–2.50) 0.21 1.51 (0.25–9.23) 0.65
Tumor type
AML 1 2.36 (0.63–8.86) 0.20 1.14 (0.81–1.61) 0.45 1.18 (0.85–1.66) 0.32 2.29 (0.61–8.60) 0.22
Etiology
De novo 1 1.58 (0.35–7.13) 0.55 1.10 (0.77–1.58) 0.59 1.12 (0.79–1.59) 0.53 1.55 (0.34–6.98) 0.57
Secondary 1 8.90 (1.56–50.94) 0.01 1.47 (0.67–3.24) 0.34 1.73 (0.83–3.63) 0.14 8.15 (1.44–46.06) 0.02
Racial decent
Asian 1 2.36 (0.63–8.86) 0.20 1.14 (0.81–1.61) 0.45 1.185 (0.85–1.66) 0.32 2.29 (0.61–8.60) 0.22
Control source
Population 1 2.36 (0.63–8.86) 0.20 1.14 (0.81–1.61) 0.45 1.185 (0.85–1.66) 0.32 2.29 (0.61–8.60) 0.22
ALL 3 1.35 (0.37–4.98) 0.65 1.13 (0.80–1.59) 0.49 1.13 (0.80–1.58) 0.49 1.28 (0.35–4.71) 0.71
Racial decent
Asian 2 1.15 (0.24–5.39) 0.86 1.20 (0.78–1.84) 0.41 1.17 (0.74–1.84) 0.50 1.07 (0.23–5.00) 0.94
Unknown 1 2.02 (0.18–22.72) 0.57 1.01 (0.57–1.81) 0.97 1.04 (0.59–1.84) 0.88 2.02 (0.18–22.54) 0.57
Control source
Population 2 1.07 (0.16–7.01) 0.94 0.99 (0.64–1.53) 0.97 0.98 (0.64–1.50) 0.92 1.07 (0.17–7.00) 0.94
Hospital 1 1.68 (0.27–10.31) 0.58 1.42 (0.80–2.51) 0.23 1.43 (0.82–2.50) 0.21 1.51 (0.25–9.23) 0.65
CML 1 0.33 (0.01–8.02) 0.49 0.36 (0.11–1.13) 0.08 0.33 (0.10–1.02) 0.05 0.33 (0.01–8.19) 0.50
Racial decent
Asian 1 0.33 (0.01–8.02) 0.49 0.36 (0.11–1.13) 0.08 0.33 (0.10–1.02) 0.05 0.33 (0.01–8.19) 0.50
Control source
Population 1 0.33 (0.01–8.02) 0.49 0.36 (0.11–1.13) 0.08 0.33 (0.10–1.02) 0.05 0.33 (0.01–8.19) 0.50
CLL 1 0.20 (0.01–4.10) 0.29 0.87 (0.57–1.32) 0.51 0.84 (0.55–1.27) 0.40 0.20 (0.01–4.16) 0.30
Racial decent
Unknown 1 0.20 (0.01–4.10) 0.29 0.87 (0.57–1.32) 0.51 0.84 (0.55–1.27) 0.40 0.20 (0.01–4.16) 0.30
Control source
Population 1 0.20 (0.01–4.10) 0.29 0.87 (0.57–1.32) 0.51 0.84 (0.55–1.27) 0.40 0.20 (0.01–4.16) 0.30

n, number of studies; unknown, including study populations in which the race was mixed or unclear; secondary, including secondary and therapy-related AML; OR, odds ratio; CI, confidence interval; P, P value.